Compare Samsara Inc (IOT) vs Novartis AG (NVS) Price & Performance

Samsara IncTrade

Novartis AGTrade

Price performance (Past 24H)

Key statistics

Samsara Inc vs Novartis AG — how do they compare? Samsara Inc trades at $36.19 (market cap $22.46B), while Novartis AG trades at $154.09 (market cap $290.25B). The key difference: Novartis AG is far larger — about 12.9× Samsara Inc's market cap, and Novartis AG pays a 3.17% dividend while Samsara Inc pays none. Which is the better fit depends on your goals.

	IOT	NVS
Market Cap	$22.46B	$290.25B
Sector	Technology	Health
52-Week High	$45.22	$168.62
52-Week Low	$24.25	$113.50
Enterprise Value	$21.73B	$330.27B
Dividend Yield	—	3.17%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Samsara Inc

Samsara (IOT) trades at $38.55, up 0.6% with strong technical momentum and bullish analyst sentiment. The stock shows robust earnings momentum with three consecutive quarterly beats, while revenue growth accelerated to $1.7B in 2026 with positive net income of $58M. Technical indicators show bullish moving averages despite overbought RSI readings, with key resistance at $39-$41. Recent product launches including AI agentic tools and tracking labels demonstrate continued innovation in connected operations.

The outlook remains positive with 78% analyst buy ratings and $44.40 consensus target offering 15% upside. However, elevated valuations (P/E 383) and negative 2025 cash flow (-$59M) present risks. Growth sustainability depends on maintaining large customer momentum and margin expansion amid AI investments. The stock presents a growth opportunity but requires monitoring of execution and valuation compression risks.

Novartis AG

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

IOT

Samsara keeps Buy rating after strong Q1 with 30% ARR growth and new AI-driven products expanding market reach.Seeking Alpha · 1 day agoBullish View details →

NVS

Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.Gordon Thompson · 21 hours agoNeutral New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral FDA approves Fabhalta as first drug to significantly slow kidney decline in IgAN patientsNovartis · 4 days agoBullish View details →

About Samsara Inc

Samsara provides a connected operations cloud that uses IoT data to help businesses improve efficiency and safety. Its platform offers real-time visibility for fleet management, equipment monitoring, and industrial sites.

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.